Background Arovella Therapeutics is a preclinical stage company developing allogeneic'off-
the-shelf'human invariant natural killer T (iNKT) cell-based therapies for hematological …

This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK)
cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a …

BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis (4-chlorophenyl) methyl]-4-N-[3-[bis (4-
chlorophenyl) methyl]-4-(dimethylamino) phenyl]-1-N, 1-N-dimethylbenzene-1, 4-diamine …

Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and
viral infections. They are 'first responders' that can spontaneously recognize abnormal cells …

Induced pluripotent stem cell (iPSC)-derived immune effector cells offer distinct advantages
over existing patient-and donor-derived therapeutic approaches, including the use of a …

FT538 is an investigational, off-the-shelf, multiplexed engineered natural killer (NK) cell
cancer immunotherapy that is derived from a clonal master induced pluripotent stem cell …

Energy metabolism is key to the promotion of tumor growth, development, and metastasis. At
the same time, cellular metabolism also mediates immune cell survival, proliferation and …

Human natural killer (NK) cell-based adoptive anticancer immunotherapy has gained
intense interest with many clinical trials actively recruiting patients to treat a variety of both …

Immune checkpoint therapy has produced remarkable improvements in the outcome for
certain cancers. To broaden the clinical impact of checkpoint targeting, we devised a …

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a novel immunotherapy
targeting cancer cells via the generation of chimeric antigen receptors on NK cells which …